Financials data is unavailable for this security.
View more
Year on year Genmab A/S had net income fall -20.18% from 5.45bn to 4.35bn despite a 13.57% increase in revenues from 14.51bn to 16.47bn. An increase in the selling, general and administrative costs as a percentage of sales from 18.19% to 19.74% was a component in the falling net income despite rising revenues.
Gross margin | 96.83% |
---|---|
Net profit margin | 29.01% |
Operating margin | 30.73% |
Return on assets | 15.59% |
---|---|
Return on equity | 18.42% |
Return on investment | 17.13% |
More ▼
Cash flow in DKKView more
In 2023, Genmab A/S increased its cash reserves by 50.28%, or 4.97bn. The company earned 7.38bn from its operations for a Cash Flow Margin of 44.80%. In addition the company used 1.28bn on investing activities and also paid 606.00m in financing cash flows.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 487.96 |
---|---|
Tangible book value per share | 259.04 |
More ▼
Balance sheet in DKKView more
Current ratio | 5.03 |
---|---|
Quick ratio | 5.02 |
Total debt/total equity | 0.0329 |
---|---|
Total debt/total capital | 0.0319 |
More ▼
Growth rates in DKK
Year on year, growth in earnings per share excluding extraordinary items dropped -20.06%. Additionally, five year annualized earnings per share growth ranks highest in its industry.
EPS growth(5 years) | 22.71 |
---|---|
EPS (TTM) vs TTM 1 year ago | 19.13 |